Introduction: MSC1992371A is an aurora kinase inhibitor with potential antitumor activity. Methods: This trial established the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral MSC1992371A given before or after gemcitabine (1,000 mg/m2) in a 21-day cycle in patients with advanced malignancies. In schedule 1 (n = 31), gemcitabine was administered on days 1 and 8 followed by escalating doses of MSC1992371A on days 2 and 9. In schedule 2 (n = 35), MSC1992371A was given on days 1 and 8 followed by gemcitabine on days 2 and 9. Patients had a range of solid tumors, the most frequent of which was colorectal (n = 19). Results: In both schedules, the 37 mg/m2 dose level was defined as the MTD. The main DLT was grade 4 neutrope...
Purpose Danusertib (PHA-739358) is a small-molecule pan-aurora kinase inhibitor. This phase I dose e...
PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase i...
Background Aurora kinase overexpression or amplifications are associated with high proliferation, po...
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, a...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...
Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
<i>Objective:</i> LY2603618, a selective inhibitor of checkpoint kinase 1 (CHK1) and key regulator o...
Purpose: This study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and preli...
Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased...
PURPOSE: To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO)...
Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in pat...
Background: To determine, for each of two dosing schedules, the dose-limiting toxicity (DLT) and max...
Purpose AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizi...
Purpose Danusertib (PHA-739358) is a small-molecule pan-aurora kinase inhibitor. This phase I dose e...
PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase i...
Background Aurora kinase overexpression or amplifications are associated with high proliferation, po...
This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, a...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...
Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and sa...
<i>Objective:</i> LY2603618, a selective inhibitor of checkpoint kinase 1 (CHK1) and key regulator o...
Purpose: This study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and preli...
Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased...
PURPOSE: To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO)...
Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in pat...
Background: To determine, for each of two dosing schedules, the dose-limiting toxicity (DLT) and max...
Purpose AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizi...
Purpose Danusertib (PHA-739358) is a small-molecule pan-aurora kinase inhibitor. This phase I dose e...
PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase i...
Background Aurora kinase overexpression or amplifications are associated with high proliferation, po...